English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

: Cancer is the leading cause of death globally according to WHO in 2020. It is initiated by genetic mutations that occur due to numerous factors. The aim of the review : This review provides a clear view of the potential use of chromosome 6 open reading frame 106 ( C6orf106 ) as a biomarker, based on previous studies. Results : Recent studies have investigated the association of C6orf106 with breast cancer and non-small cell lung cancer and showed that silencing C6orf106 leads to inhibition of malignancy in both diseases, as well as showing a positive correlation between C6orf106 expression and malignancy. Other studies demonstrated the interaction of C6orf106 with other malignancy factors that play a role in many cancer types, such as cyclin A2, cyclin B1, N-cadherin, E-cadherin, c-MYC, p120ctn, and vimentin. These factors play a significant role in cellular adhesion and the regulation of the cell cycle. C6orf106 is a potential target for numerous cancers, not only non-small cell lung cancer and breast cancer. In conclusion : understanding the connection of C6orf106 with crucial malignancy factors makes it clear that C6orf106 is a potential therapeutic target and diagnostic biomarker for many disease cancer.

Association of chromosome 6 open reading frame 106 in different cancers